BIAF
bioAffinity·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 2
Bearish signal 1
Stock Price Surged Significantly
Ample Liquidity
Significant Net Income Decline
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About BIAF
Bioaffinity Technologies, Inc.
A company that develops proprietary noninvasive diagnostic tests and cancer therapeutics to diagnose early-stage cancer
Healthcare Equipment and Supplies
03/26/2014
09/01/2022
NASDAQ Stock Exchange
57
12-31
Common stock
22211 W Interstate 10, Suite 1206, San Antonio, Texas 78257
--
BioAffinity Technologies, Inc., was incorporated in Delaware on March 26, 2014. The company focuses on non-invasive diagnostic needs for early-stage cancer and lung diseases, and targets cancer therapy. The company has developed a proprietary platform for in vitro diagnostics, the first of which is a non-invasive test for early detection of lung cancer. The company's diagnostic tests are based on platform technologies that may be applicable to the detection of other lung diseases such as chronic obstructive pulmonary disease (COPD) and asthma, as well as the diagnosis of cancer types such as prostate and bladder cancer.
Company Financials
EPS
BIAF has released its 2025 Q3 earnings. EPS was reported at -4.74, versus the expected -2.7, missing expectations. The chart below visualizes how BIAF has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
BIAF has released its 2025 Q3 earnings report, with revenue of 1.45M, reflecting a YoY change of -38.48%, and net profit of -5.05M, showing a YoY change of -152.45%. The Sankey diagram below clearly presents BIAF's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
